WHO International Standard
1st International Standard for antibodies to SARS-CoV-2 variants of concern
NIBSC code: 21/338
Instructions for use
(Version 2.0, Dated 09/12/2022)

§

1. INTENDED USE
The 1st WHO International Standard for antibodies to SARS-CoV-2 variants of concern (VOC) is the freeze-dried equivalent of 0.25 mL of pooled plasma obtained from 265 individuals infected with one of the early 2020 SARS-CoV-2 isolates or a VOC (including Alpha, Beta and Delta). All individuals were vaccinated with one or more of these vaccines: Pfizer/BioNTech Comirnaty, Moderna Spikevax, Oxford/AstraZeneca Covishield/Vaxzevria, Sinopharm BBIBP/CorV, Johnson & Johnson/Janssen Jcovden. The preparation has been evaluated in a WHO International Collaborative study (1). The preparation has been prepared treated to minimise the risk of the presence of enveloped viruses (2).

The intended use is for the calibration and harmonization of serological assay detecting neutralising antibodies to SARS-CoV-2 variants of concern circulating during or after 2022, such as Omicron sub-lineages. The preparation does not contain any convalescent plasma from Omicron-infected individuals; however, in the collaborative study, 21/338 has shown neutralising activity against Omicron BA.1 and BA.2 (1). Feedback received from users has also confirmed neutralising activity against BA.4 and BA.5.

The standard should be used for comparison of results between neutralisation assays using the same variant, not between variants.

2. CAUTION
The preparation contains material of human origin, and either the final product or the source materials, from which it is derived, have been tested and found negative for HBsAg, anti-HIV and HCV RNA. This preparation is not for administration to humans or animals.

As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory’s safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE
The assigned unitage of the 1st WHO International Standard for antibodies to SARS-CoV-2 variants of concern is 4250 IU/ampoule for neutralising antibody activity against Omicron sub-lineages and other VOC which should emerge after June 2022. After reconstitution in 0.25 mL of distilled water, the final concentration of the preparation is 17000 IU/mL. Prior to establishment as an International Standard, 21/338 was available as a Working Standard with neutralising antibody potencies relative to the First WHO International Standard for anti-SARS-CoV-2 immunoglobulin, 20/136, as reported below. These values are based on the geometric mean of the results from the assays used in the collaborative study together with the 95% confidence interval (95% CI) and are intended for guidance only.

4. CONTENTS
Country of origin of biological material: United Kingdom and Cameroon.
Each ampoule contains the equivalent of 0.25 mL of human plasma.

5. STORAGE
21/338 should be stored at -20°C or below upon receipt.
Please note because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.

6. DIRECTIONS FOR OPENING
DIN ampoules have an 'easy-open' coloured stress point, where the narrow ampoule stem joins the wider ampoule body. Various types of ampoule breaker are available commercially. To open the ampoule, tap the ampoule gently to collect material at the bottom (labelled) end and follow manufactures instructions provided with the ampoule breaker.

7. USE OF MATERIAL
No attempt should be made to weigh out any portion of the freeze-dried material prior to reconstitution.
This material should be reconstituted in 0.25 mL distilled water. Following addition of water, the ampoules should be left at ambient temperature for approximately 30 minutes until dissolved and then mixed thoroughly, avoiding the generation of excessive foam.

8. STABILITY
Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label.
NIBSC follows the policy of WHO with respect to its reference materials.

9. REFERENCES
(1) Bentley EM et al. Establishment of the 2nd WHO International Standard for antibodies to SARS-CoV-2 variants of concern. 2022, WHO Expert Committee on Biological Standardization, WHO/BS/2022.2427

10. ACKNOWLEDGEMENTS
We would like to wholeheartedly thank the anonymous donors of the plasma samples for their consent which has allowed this study to be undertaken. We thank our partner organizations for the recruitment of the donors and provision of the material: NHS Blood and Transplant (United Kingdom), Influss Health (NY, USA and Cameroon), and NIBSC employees. Provision of the convalescent plasma by ISARIC4C was supported by grants from: the National Institute for Health Research (NIHR; award CO-CIN-01), the Medical
Research Council (MRC; grant MC_PC_19059), and by the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with UK Health Safety Agency (UKHSA), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford (award 200907), NIHR HPRU in Respiratory Infections at Imperial College London with UKHSA (award 200927), Wellcome Trust and Page 2 of 2 Department for International Development (DID; 215091/Z/18/Z), the Bill and Melinda Gates Foundation (OPP1209135), Liverpool Experimental Cancer Medicine Centre (grant reference C18816/A25153), NIHR Biomedical Research Centre at Imperial College London (IS-BRC-1215-20013), EU Platform for European Preparedness Against (Re-emerging Epidemics (PREPARE; FP7 project 602525), and NIHR Clinical Research Network for providing infrastructure support for this research. We would also like to thank MHRA Standards Production team for the formulation of the standards; Graham Prescott and Katrina Ternouth for the blood virology testing and Corinne McDonough for the distribution of study samples. The project has been funded by the Coalition for Epidemic Preparedness Innovations.

11. FURTHER INFORMATION
Further information can be obtained as follows;
This material: enquiries@nibsc.org
WHO Biological Standards:
http://www.who.int/biologicals/en/
JCTLM Higher order reference materials:
http://www.biopm.org/en/committees/jc/jctlm/
Derivation of International Units:
http://www.nibsc.org/standardisation/international_standards.aspx
Ordering standards from NIBSC:
http://www.nibsc.org/products/ordering.aspx
NIBSC Terms & Conditions:
http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK
Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION
In all publications, including data sheets, in which this material is referenced, it is important that the preparation’s title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET
Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

---

### Toxicological properties

<table>
<thead>
<tr>
<th>Effects of inhalation:</th>
<th>Not established, avoid inhalation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effects of ingestion:</td>
<td>Not established, avoid ingestion</td>
</tr>
<tr>
<td>Effects of skin absorption:</td>
<td>Not established, avoid contact with skin</td>
</tr>
</tbody>
</table>

### Suggested First Aid

- **Inhalation:** Seek medical advice
- **Ingestion:** Seek medical advice
- **Contact with eyes:** Wash with copious amounts of water. Seek medical advice
- **Contact with skin:** Wash thoroughly with water.

### Action on Spillage and Method of Disposal

Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate disinfectant. Rinse area with an appropriate disinfectant. Absorbent materials used to treat spillage should be treated as biological waste.

---

15. LIABILITY AND LOSS
In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents. Unless expressly stated otherwise by NIBSC, NIBSC’s Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) (“Conditions”) apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient’s attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY

- **Country of origin for customs purposes:** United Kingdom
- **Net weight:** 0.25 g
- **Toxicity Statement:** Non-toxic
- **Veterinary certificate or other statement if applicable:** Attached: No

17. CERTIFICATE OF ANALYSIS
NIBSC does not provide a Certificate of Analysis for WHO Biological Reference Materials because they are internationally recognised primary reference materials fully described in the instructions for use. The reference materials are established according to the WHO Recommendations for the preparation, characterization and establishment of international and other biological reference standards http://www.who.int/bloodproducts/publications/TRS932Annex2_Inter_biolefstandardsrev2004.pdf (revised 2004). They are officially endorsed by the WHO Expert Committee on Biological Standardization (ECBS) based on the report of the international collaborative study which established their suitability for the intended use.